Vanda Pharmaceuticals Inc. income statement

In fiscal 2025, Vanda Pharmaceuticals Inc. reported revenue of $216m, up 8.7% on the year before, operating income of −$151m (a -70.0% margin) and net income of −$220m, or −$3.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Vanda Pharmaceuticals Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	5	36	31	33	34	50	110	146	165	193	227	248	269	254	193	199	216	229
Research and development	14	12	29	46	29	19	29	29	39	44	49	56	75	86	77	74	109	122
Selling, general and administrative	—	—	—	15	25	85	85	100	124	106	130	141	124	136	113	146	238	263
General and administrative	24	10	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating income	−36	9	−11	−29	−21	20	−40	−19	−17	22	23	27	42	6	−14	−41	−151	−178
Income before tax	−36	9	−10	−28	−20	20	−40	−18	−15	25	29	32	42	11	6	−23	−139	−171
Income tax	—	2	−0	—	0	0	0	0	0	0	−87	8	9	5	4	−4	82	104
Net income	−36	7	−10	−29	−21	20	−40	−18	−16	25	116	23	33	6	3	−19	−220	−275
Diluted EPS	−$1.33	$0.25	−$0.35	−$1.01	−$0.69	$0.55	−$0.94	−$0.41	−$0.35	$0.48	$2.11	$0.42	$0.58	$0.11	$0.04	−$0.33	−$3.74	−$4.59
Diluted shares (average)	27m	29m	28m	28m	30m	37m	42m	43m	45m	53m	55m	55m	57m	57m	58m	58m	59m	60m
EBITDA	−36	9	−10	−29	−21	21	−40	−18	−16	23	24	29	44	8	−13	−40	−150	−177

US$ millions unless shown otherwise. Fiscal quarters.

Vanda Pharmaceuticals Inc.: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	53	50	53	56	57	52	51	70
Research and development	20	36	22	23	29	28	37	28
Selling, general and administrative	39	50	65	60	63	68	72	60
Operating income	−10	−41	−39	−31	−40	−50	−64	−24
Income before tax	−6	−37	−35	−28	−38	−48	−62	−22
Income tax	−2	−8	−8	−6	103	0	0	0
Net income	−5	−29	−27	−23	−141	−49	−63	−23
Diluted EPS	−$0.09	−$0.50	−$0.46	−$0.38	−$2.39	−$0.82	−$1.04	−$0.37
EBITDA	−10	−41	−38	−31	−40	−50	−64	−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACB vs VNDA HROW vs VNDA OGI vs VNDA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Vanda Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vanda Pharmaceuticals Inc.